Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $.001
-
Shares outstanding
-
65.8M
-
Number of holders
-
156
-
Total 13F shares, excl. options
-
43.2M
-
Shares change
-
+7.59M
-
Total reported value, excl. options
-
$2.33B
-
Value change
-
+$430M
-
Put/Call ratio
-
0.69
-
Number of buys
-
92
-
Number of sells
-
-61
-
Price
-
$53.99
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) as of Q3 2021
192 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $.001 as of Q3 2021.
Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) has 156 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 43.2M shares
of 65.8M outstanding shares and own 65.66% of the company stock.
Largest 10 shareholders include FMR LLC (5.62M shares), RTW INVESTMENTS, LP (3.91M shares), BlackRock Inc. (3.13M shares), Redmile Group, LLC (3.04M shares), VANGUARD GROUP INC (2.28M shares), WELLINGTON MANAGEMENT GROUP LLP (2.18M shares), STATE STREET CORP (1.86M shares), RA CAPITAL MANAGEMENT, L.P. (1.6M shares), EVENTIDE ASSET MANAGEMENT, LLC (1.13M shares), and VR Adviser, LLC (1.1M shares).
This table shows the top 156 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.